Propanc Biopharma, Inc. (OTCQB:PPCB)’s Post

Name: How Propanc Biopharma optimized lead asset formulation | Propanc Biopharma, Inc. (OTCQB:PPCB) posted on the topic | LinkedIn
Uploaded: 2024-05-02T18:04:38.756Z
Duration: 3 min 57 s
Channel: Propanc Biopharma, Inc. (OTCQB:PPCB)

Propanc Biopharma, Inc. (OTCQB:PPCB)

215 followers

8mo Edited

How has Propanc Biopharma optimized the formulation of their lead asset? We invite you to listen as Dr. Ralf Brandt, Propanc’s Scientific Advisory Board Member & Co-Inventor describes the process for taking the formulation from that compassionate use study that observed such positive results, and how the team further improved that same formulation with the goal of seeing even more efficacious results! #propanc #ppcb #biopharma #cancer #oncology

Transcript

So which is one of the the missing parts from a lot of models to to get the results? Forecasted for the outcome in the clinic. So we will found was specializing at that time when I met with James and and two major parts which were driving our relationship for success of that formulation that's combination studies in vitro means in the Petri dish and also in vivo with animal models. And the other part is orthotopic tumor models are whereas most of our competitors CEO's had injected anti cancer drug. Dates into animals which subcutaneous tumors. But it is absolutely clear that tumors are not growing under the skin somewhere. So they are in the target organs. And we have specialized in these target organ models called orthotopic models and have good models for pancreatic cancer, colon cancer and ovary. And so that that maybe as an introduction when I got contacted by James with that original formulation, I immediately asked the question is the ratio of the two components. The pro enzymes optimize. Has anybody looked into it, one whether the one or the other is acting better in a higher or lower concentration. So that we did then in vitro studies against target cell lines for the cancers mentioned to see whether there is any optimization possible about the ratio. We came up with the ratio of one to six or six and one the other way and and that has provided us much better outcome already in the Petri dish which has then been translated into our animal studies. With pancreatic colon and over ovarian cancers with a very to me surprising outcome as well as as Julian mentioned because there was no historical data and normally people would say that can't work because there was not clear what the mechanism is which had been elucidated a little bit later at least from a point of hypothesis backed up with some data. So we got impressive results in inhibiting tumors up to 70% I have to say here also. That we we our setups of models where going into the direction only to inhibit tumors. So we had not looked into questions like a differentiation of cells or any change in morphology of cells and knowing that an orthotopic tumors you have a lot of interaction with the stroma cells surrounding the tumor. We had an idea that there is a special effect on changing that interaction, but we didn't study it. So that was then later done by partners. With with propane which have them found that the interaction between the stroma and the tumor cells or the tumor itself is changing so that that that process was not called epithelium isn't shimmery transition and that is also inhibited by the formulation which was found later. And that is an explanation that in principle maybe we don't see a total regression of tumor, we see a slowdown of tumors because the tumor cells are reversing into their. You can heal your state meaning they are more differentiated. So and and we know from outcome of clinical studies, I hope I say the right Julian that more differentiated tumors have normally a better outcome. So if we can reverse the effect. Of these rumors, at least yours on the animal model to bring them back in a more differentiated stage than there is a very good chance that you have a longer disease free outcome. And maybe combining and that's an idea I would bring in, in further discussions of models and combining it with other types or metronomic therapies you might have have a very long lasting survival effect with that treatment.

To view or add a comment, sign in

More Relevant Posts

Mauricio Z. Baptista, MD, PhD

Medical Oncologist
4mo
Report this post
Just In: The Breast Cancer Drug Market In 2023, sales of leading breast cancer drugs reached approximately $28 billion. The primary agents driving this growth were CDK4/6 inhibitors and HER2-targeted therapies. For a deeper dive into emerging treatments & market trends, explore this latest analysis 👉 https://lnkd.in/dU-sKFqe @NatRevDrugDisc #bcsm #trendings
Like Comment
To view or add a comment, sign in
Daja Herald

Marketing Executive | Content Creator | Digital Marketer | Inbound Marketing Enthusiast
4mo
Report this post
Join your peers for this must-attend #webinar reviewing different types of linkers and payloads used in antibody-drug conjugates, as well as key methodologies involved in developing robust bioassays for #ADCs. Register today to gain access to the live event and on-demand recording. #medicinalchemistry #biotechnology #ADC #cellbasedassay #drugdiscovery #biology #chemistry #CDMO
Curia

83,128 followers
4mo Edited

Antibody-drug conjugates are transforming #cancer therapy. Join our upcoming webinar with BioProcess Online to learn more from our experts. David Manning and Yunpeng Pang (YP) will share their journey in enhancing #ADC efficacy and safety, providing valuable insights into the future of targeted treatments. >>> Register now and stay ahead in the biotech field! https://ow.ly/Ak5g50SELlC --- Learn more about our end-to-end CDMO expertise: https://ow.ly/vKht50SGyj4 #ADCBreakthroughs #BiotechInnovation #Curia #CDMO #oncology
Like Comment
To view or add a comment, sign in
Roy Maute

Co-founder and Chief Executive Officer at Pheast Therapeutics
4mo
Report this post
In addition to being asked, “Why CD24?” – I also get asked, “How is your lead drug candidate, PHST001, differentiated?” Due to the complex glycosylation patterns on CD24, not all antibodies against this target are created equal. We have engineered PHST001 to interact with all glyco-variants of CD24, which enables potent activity. And our preclinical data show that we are on the right track. Macrophage checkpoint inhibitors hold tremendous promise, and I believe that PHS001 can strike the right balance of safety and efficacy that is crucial to success. Thanks @PharmaShots for the opportunity to discuss the potential impact of PHST001, how it works, and the impact it could make on the field of cancer immunotherapy.
Pheast Therapeutics

3,833 followers
4mo

Our CEO and cofounder Roy Maute recently chatted with PharmaShots about how our lead candidate, PHST001 uniquely targets CD24 as a differentiated macrophage checkpoint inhibitor, what our preclinical data is telling us, and our plans for clinical trials. Read the Q&A here: https://lnkd.in/e9XjrmPF #immunotherapy #cancer #oncology #drugdevelopment #pharma #macrophages #macrophage #checkpointinhibitors #CD24
5 Comments
Like Comment
To view or add a comment, sign in
Zai Lab

25,516 followers
1mo Edited
Report this post
#ICYMI: Data from the ongoing global Phase 1 study of our investigational DLL3-targeted antibody-drug conjugate were featured in several news outlets, including Endpoints News, FirstWord Pharma and Cancer Network. To read more about how we’re continuing to develop a potential best-in-class, next-generation #ADC, visit https://bit.ly/3UoeXhv #innovation #SCLC #lungcancer #cancernews #oncology
Like Comment
To view or add a comment, sign in
myTRIAList

324 followers
5mo
Report this post
Facilitate better #patientcare through education. Our "What is a Clinical Trial?" video on myTRIAList.org is designed to demystify the clinical trial process for patients. Watch here: https://buff.ly/46dnA2g #cancer #oncology #hematology #cancerresearch #clinicaltrials #medicaleducation #pharma #biotech CancerCare

Free Patient Clinical Trial Education Resources

1 Comment
Like Comment
To view or add a comment, sign in
myTRIAList

324 followers
6mo
Report this post
Did you know that the myTRIAList trial finder includes trial overview videos, like the MOUNTAINEER-03 trial, that feature investigator testimonies and plain language summaries that explain the trial to people living with cancer and their caregivers? Check out the trial finder to learn more about cancer clinical trials here: https://buff.ly/3XelQE7 #colorectalcancer #oncology #pharma #biotech #clinicaltrials CancerCare
Like Comment
To view or add a comment, sign in
Laboratory Testing Division, Drug Discovery and Development

2,422 followers
4mo
Report this post
The precision of LC-MS/MS is a game-changer in the development of antibody-drug conjugates (ADCs), essential for advancing oncology. By providing a detailed analysis of ADC components, LC-MS/MS ensures that new treatments are effective and safe for patients. Explore how this powerful analytical tool is paving the way for better cancer treatment outcomes. #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GcTHJ0

The Advantages of LC-MS/MS in Optimizing ADC Bioassays
Like Comment
To view or add a comment, sign in
Larka

1,990 followers
1mo
Report this post
Big Pharma’s interest for antibody-drug conjugates (ADCs) is skyrocketing. The increased volume in dealmaking reflects the potential of #ADC as a targeted #cancer therapy—and investments are expected to carry on as the modality continues to build up clinical and commercial acceptance. Explore Pharma top 10 companies’ favourite therapeutic areas and drug modalities for M&A in our latest report: https://lnkd.in/d8SXc-v7
Like Comment
To view or add a comment, sign in
Cancer Research Horizons

15,474 followers
9mo
Report this post
#AACR24, here we come! We can’t wait to share with you the latest from our #DrugDiscovery labs next Monday. Here’s a preview 👇 💡 Abstract 2945 / 20: Find out how our #FunctionalGenomicsCentre’s teams are reducing the experimental scale of #CRISPR screens by 50%. 💡 Abstract 3333 / 21: Learn about ASTX295, a potent inhibitor of the MDM2-p53 interaction currently under clinical investigation. Are you presenting at #AACR24? Let us know where and when in the comments. #OnMyHorizon #Oncology Steve Wedge, David Walter, Astex Pharmaceuticals and American Association for Cancer Research

4 Comments
Like Comment
To view or add a comment, sign in
Sharewise

654 followers
6mo
Report this post
Watch our webinar with Amplia Therapeutics Limited, featuring CEO and MD Chris Burns. The webinar will commence with a presentation, followed by a live Q&A with the audience, providing you the opportunity to ask Chris any questions about ATX that you may have. Key topics: - Data from recent trial - Why ovarian and pancreatic cancer? - What are the next key milestones and value drivers? - Where were the drugs discovered? Register here: https://hubs.la/Q02zctXZ0
Like Comment
To view or add a comment, sign in

215 followers

View Profile Follow

Propanc Biopharma, Inc. (OTCQB:PPCB)’s Post

Transcript

More Relevant Posts

Free Patient Clinical Trial Education Resources

Explore topics